^
Association details:
Biomarker:FGFR1 mutation
Cancer:Solid Tumor
Drug:Lytgobi (futibatinib) (FGFR inhibitor)
Direction:Sensitive
Evidence:
Evidence Level:
Sensitive: C3 – Early Trials
Source:
Title:

Efficacy and safety of futibatinib for refractory advanced solid malignancies with FGFR alterations identified in circulating tumor DNA: TiFFANY, A GOZILA-affiliated Trial.

Published date:
05/25/2023
Excerpt:
Futibatinib demonstrated promising efficacy in refractory advanced solid malignancies with FGFR alterations in ctDNA with an acceptable toxicity profile. Oncogenic co-alterations detected by ctDNA genotyping may predict primary resistance.
DOI:
10.1200/JCO.2023.41.16_suppl.3102